LMTX News - Candlesense

Larimar Therapeutics Reports Second Quarter 2025 Financial Results

*Pro forma cash, cash equivalents, and marketable securities of $203.6 million reflects $138.5 million of cash, cash equivalents and marketable securities as of June 30, 2025 combined with the $65....

How does this capital raise impact the company’s long‑term strategic plan and partnership opportunities? Will the market re‑price the stock based on the improved balance sheet and reduced financing risk? What are the potential risks if the company fails to meet its projected cash‑burn rate?

Earnings

28 days ago